GET DAILY SIGNALSWhy Is Supernus Pharmaceuticals (SUPN) Stock Down -17.01% Today?
Key Takeaways
- SUPN shares fell roughly 17.01% to $30.11, down from a prior close of $36.28, in the first session of trading as the newly merged Supernus–Indivior company.
- The move followed the completion of the merger between Supernus Pharmaceuticals and Indivior, with the combined entity beginning to trade under the SUPN ticker on November 3, 2026.
- Secondary pressures included a new $650 million term loan used to fund a $1 billion special cash dividend to former Indivior stockholders, along with share dilution from the exchange-ratio conversion.
- The stock broke below its prior trading range and moving averages, reflecting post-merger revaluation and integration uncertainty.
- Traders are watching for integration execution, realization of the targeted $125 million in annual cost synergies, and the combined company's next earnings report.
- For more context on this ticker, explore Price Targets, Earnings, and Forecast pages for additional data and analysis.
- Interested in automated trading strategies? Explore Trending AI Robots to see the strongest-performing AI bots under current market conditions.
Opening Summary
Supernus Pharmaceuticals (SUPN), a specialty biopharmaceutical company focused on central nervous system (CNS) diseases, saw its shares tumble approximately 17.01% in trading on November 3, 2026. The stock fell to $30.11 from a prior closing level of $36.28, a decline of $6.17 per share. The sell-off marked the first day of trading for the combined company created by the completed merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, which now operates as Supernus, Inc. under the SUPN symbol. Markets attributed the decline to post-merger revaluation, the debt taken on to fund a special dividend, and near-term integration uncertainty.
Merger Completion and First-Day Revaluation
The dominant catalyst behind the move was the closing of the all-stock merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals, announced in August 2026 and completed on November 2, 2026. Under the terms of the deal, Supernus stockholders received 1.5401 shares of Indivior common stock for each share held, while Indivior stockholders received a one-time special cash dividend of $1 billion in aggregate. Following the transaction, the combined company adopted the Supernus name and began trading on the Nasdaq Global Market under the SUPN ticker on November 3, replacing the prior Indivior listing.
First-day trading in a merged entity often brings a repricing as index funds, arbitrageurs, and investors that held shares specifically for the merger exit their positions. The combination creates a diversified CNS platform spanning an 11-product portfolio across opioid use disorder, psychiatry, and neurology, anchored by five core growth drivers including SUBLOCADE, Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE. Despite the strategic rationale, the shares sold off as the market absorbed the newly issued share count and reassessed the combined company's valuation.
Debt Financing and the Special Dividend
A second driver was the balance-sheet impact of the transaction's financing. To fund the $1 billion special dividend paid to former Indivior stockholders, the companies drew on a $650 million senior secured term loan facility, with the remainder funded from existing cash. The addition of roughly $650 million in new debt to the combined balance sheet weighed on sentiment, as investors reassessed leverage and the company's near-term financial flexibility at a time when integration spending is still ramping up.
Market Context and Trading Activity
Trading volume was elevated around the merger completion, consistent with heavy positioning and rebalancing flows rather than ordinary daily turnover. The stock broke below its prior trading range and fell beneath key moving averages as the combined entity's share price repriced lower, reflecting both the dilution from the share exchange and the debt-funded dividend payout. The move was company-specific in nature; broader market indices and the healthcare sector did not show a comparable sell-off, underscoring that the decline was driven by the merger mechanics and post-deal integration outlook rather than a broad risk-off environment.
What Comes Next for SUPN
Looking ahead, the focus shifts to execution. Management has signaled a target of roughly $125 million in annual cost synergies from the integration of Supernus and Indivior, and investors will closely track progress against that goal in the coming quarters. Key catalysts include the combined company's next earnings release, updates on the performance of its five core growth products, and the advancement of late-stage pipeline candidates. Risks include the complexity of integrating two commercial organizations, the weight of the newly added debt, and any disruption to product momentum during the transition. Until clearer integration milestones are reported, volatility in SUPN shares may persist.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading bots. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, but only those delivering standout results under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots page to discover which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SUPN's RSI Oscillator ascends from oversold territory
The RSI Indicator for SUPN moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 22 of the 26 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SUPN as a result. In 77 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for SUPN just turned positive on October 22, 2026. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 224 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for SUPN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.367) is normal, around the industry mean (8.029). P/E Ratio (-21.833) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (2.863) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer for the treatment of central nervous system
Industry PharmaceuticalsGeneric
Advertisement